Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. by Ferreira, João Pedro et al.
Eplerenone versus placebo renal function stratified dose comparisons in the EMPHASIS-HF 
trial  
João Pedro Ferreira1,2; Paula Abreu3; John J. V. McMurray4; Dirk J. van Veldhuisen5; Karl 
Swedberg6; Stuart J. Pocock7; John Vincent3; Katharina Lins3; Patrick Rossignol1; Bertram Pitt8; Faiez 
Zannad1 
 
1 National Institute of Health and Medical Research (INSERM), Center for Clinical Multidisciplinary 
Research 1433, INSERM U1116, University of Lorraine, Regional University Hospital of Nancy, 
French Clinical Research Infrastructure Network (F-CRIN) Investigation Network Initiative-
Cardiovascular and Renal Clinical Trialists (INI-CRCT), Nancy, France.  
2 Department of Physiology and Cardiothoracic Surgery, Cardiovascular Research and Development 
Unit, Faculty of Medicine, University of Porto, Porto, Portugal. 
3 Pfizer Inc., New York, USA. 
4 BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK. 
5 Department of Cardiology, University Medical Center Groningen, University of Groningen, 
Groningen, The Netherlands. 
6 University of Gothenburg, Gothenburg, Sweden. 
7 Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK. 
8 Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan. 
 
Corresponding author: Pr Faiez Zannad 
Centre d’Investigations Cliniques-INSERM CHU de Nancy 
Institut Lorrain du Cœur et des Vaisseaux Louis Mathieu 
4 rue du Morvan 
54500 Vandoeuvre Lès Nancy 
France 
Tel : +33 3 83 15 73 20 
Fax : +33 3 83 15 73 24 
f.zannad@chru-nancy.fr 
 
Word-count: 2152 (excluding abstract and references) 
 
 
 
Abstract 
Background: Current heart failure (HF) guidelines recommend target eplerenone dose of 50mg/day. 
We have examined the effect of different eplerenone doses based on prespecified renal function 
stratification in the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms 
(EMPHASIS-HF) trial. 
Methods: In EMPHASIS-HF, the target dose of eplerenone/placebo was stratified at randomisation 
according to estimated glomerular filtration rate (eGFR): 50mg/day if eGFR ≥50ml/min/1.73m2 and 
≤25mg/day if eGFR30-49ml/min/1.73m2. Patients remained within these dose ranges during the trial 
(per stratification). The primary outcome was a composite of heart failure hospitalization (HFH) or 
cardiovascular mortality (CVM).  
Results: Eplerenone was superior to placebo within each respective eGFR stratum: hazard ratio (HR) 
eplerenone vs. placebo in the eGFR ≥50ml/min/1.73m2 stratum=0.58 (0.45-0.74) and HR in the eGFR 
30-49ml/min/1.73m2 stratum=0.62 (0.49-0.78); p for interaction=0.89. Despite receiving lower 
eplerenone doses patients in the eGFR30-49ml/min/1.73m2 stratum had more often hyperkalemia, 
renal failure events, and drug discontinuation.   
Conclusion: In EMPHASIS-HF the eplerenone effect was not influenced by the eGFR. Patients with 
impaired renal function experienced more adverse events despite receiving lower eplerenone doses. 
The current guidelines do not specify eplerenone dose recommendation according to renal function 
and should thus be adapted in the light of these data.  
 
Key-words: eplerenone, heart failure, treatment dose, renal function, stratification. 
 
ClinicalTrials.gov identifier: NCT00232180 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Current heart failure (HF) guidelines recommend up-titration of angiotensin converting enzyme 
inhibitor (ACEi), angiotensin receptor blocker (ARB), and beta-blocker (BB) doses to evidence-based 
targets based upon those used in pivotal clinical trials in heart failure with reduced ejection fraction 
(HFrEF). In ordinary practice, these doses are not attained in many patients despite the randomized 
evidence showing the benefit of higher ACEi/ARB and BB doses1-6.  
By contrast, there is no study comparing different doses of a mineralocorticoid receptor 
antagonists (MRA)7. For eplerenone, the current guidelines recommend a starting dose of 25 mg/day 
and a target dose of 50 mg/day regardless of renal function1, 2.  
In the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial 
(EMPHASIS-HF), eplerenone reduced the risk of death and the risk of hospitalization, compared with 
placebo, in patients with heart failure and reduced left ventricular ejection fraction (LVEF) who were 
in New York Heart Association (NYHA) functional class II at the time of randomization8. Because of 
pharmacokinetic and safety considerations, patients were stratified at randomization to either a higher 
target dose (50 mg/day) of placebo/eplerenone or to a lower target dose (up to 25 mg/day), according 
to estimated glomerular filtration rate (eGFR) strata. We used this pre-specified dose-stratification to 
compare the efficacy and safety of low-dose eplerenone vs. low-dose placebo and high-dose 
eplerenone vs. high-dose placebo by renal function strata. 
 
Methods 
EMPHASIS-HF trial design 
The design of EMPHASIS-HF is published8. In short, EMPHASIS-HF was a randomized, double-
blind trial in which 2,737 patients in NYHA functional class II and with LVEF ≤35% were 
randomized to eplerenone or placebo, added to other recommended therapies. The primary outcome 
was a composite of death from cardiovascular causes (CVM) or hospitalization for heart failure 
(HFH). The median duration of follow-up was 21 months. The primary outcome occurred in 18.3% of 
patients in the eplerenone group, compared with 25.9% in the placebo group: HR (95%CI) =0.63 
(0.54-0.74); p<0.001.  
Eplerenone dose attribution and adjustment 
Patients were stratified to receive “high-dose” or “low-dose” study treatment according to eGFR as 
per stratification protocol. The main reason why a lower target dose of eplerenone was chosen in 
patients with an eGFR between 30 and 49 ml/min/1.73 m2 was because in the Eplerenone Post–Acute 
Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)9, where no prespecified 
dose allocation was performed, patients with eGFR <50 ml/min/1.73m2 had higher incidence of 
serious hyperkalemia with eplerenone compared to placebo (10.1% vs. 5.9%; p =0.006), whereas in 
patients with an eGFR ≥50 ml/min/1.73m2 the corresponding hyperkalemia rates were much lower 
(4.6 % vs. 3.5%; p =0.04). In order to avoid excessive side-effects in high-risk patients with impaired 
renal function, these received lower study drug doses by protocol prespecification.  
In concordance, placebo/eplerenone was started at a dose ≤25 mg/day and could be increased 
after 4 weeks up to 50 mg/day if the eGFR was ≥50 ml/min/1.73 m2; or started at 25 mg on alternate 
days, and increased to 25 mg/day if the eGFR was 30 to 49 ml/min/1.73 m2. By protocol, 
eplerenone/placebo doses were maintained in these dose ranges with drug-dose adjustments allowed 
according to potassium levels, as follows: if the serum potassium level was 5.5 to 5.9 mmol/L the 
study drug dose would be decreased and if the serum potassium level was ≥6.0 mmol/L the study drug 
would be temporarily stopped. Potassium was to be re-measured within 72 hours after the dose 
reduction or study-drug withdrawal, and the study drug was to be restarted only if the level was below 
5.0 mmol/L.  
Statistical analysis 
In descriptive analyses, continuous variables are expressed as mean ± standard deviation (SD). 
Categorical variables are expressed as frequencies and proportions (%). Comparison of patients in the 
low-dose and high-dose strata and within each dose strata (placebo versus eplerenone) was performed 
using an independent samples t-test and a chi-square test for categorical variables. Normality 
assumptions were verified.  
The primary outcome was a composite of HFH or CVM. Cox proportional hazard regression 
models were used to model long-term event rates both in univariable and multivariable analysis. Cox 
proportional-hazards assumptions were assessed and no violations were found. The variables used to 
adjust outcomes  were those used in a published risk model developed in EMPHASIS-HF10 i.e., age, 
sex, systolic blood pressure (SBP), eGFR11, diabetes, prior HFH, haemoglobin, prior myocardial 
infarction (MI)/coronary artery bypass grafting (CABG), body mass index (BMI).  
All analyses were performed with SAS® software version 9.4 (SAS Institute Inc., Cary, N.C., 
USA). 
 
Results 
Characteristics of the study population 
Within the respective eGFR stratum the randomization resulted in treatment groups that were well 
balanced in terms of their clinical characteristics, in accordance with the study overall. Table 1.  
Comparison of eplerenone and placebo doses during the trial by eGFR strata 
The mean eplerenone/placebo doses in the eGFR ≥50ml/min/1.73m2 stratum were of 25 mg/day at the 
study start, increased to ≥40 mg/day at week 4 and were maintained stable at ≥40 mg/day during the 
trial. Table 2. The mean eplerenone/placebo doses in the eGFR 30-49ml/min/1.73m2 stratum were 
inferior to 17 mg/day at the study start, increased up to 23 mg/day at week 4 and did not exceed 30 
mg/day during the trial. Table 2. 
Comparison of eplerenone with placebo by eGFR strata  
The event rate reduction with eplerenone compared to placebo was similar within each eGFR stratum: 
HR eplerenone vs. placebo in the eGFR ≥50ml/min/1.73m2 stratum =0.58 (0.45-0.74) and HR 
eplerenone vs. placebo in the eGFR 30-49ml/min/1.73m2 stratum =0.62 (0.49-0.78); between strata p 
for interaction =0.89. Table 3 & Figure 1.  
Adverse events 
Hyperkalemia (K+ >5.5 mmol/L) was more frequent with eplerenone compared to placebo regardless 
of the eGFR stratum. However, hyperkalemia, renal failure and drug discontinuation were more 
frequent with low-dose eplerenone/placebo (i.e., eGFR 30-49ml/min/1.73m2 stratum) compared with 
high-dose (i.e., eGFR ≥50ml/min/1.73m2 stratum). For example, hyperkalemia was observed in 1% 
and 4% of patients randomized to placebo and eplerenone, respectively, in the eGFR 
≥50ml/min/1.73m2 stratum, whereas in the eGFR 30-49ml/min/1.73m2 stratum these proportions 
increased to 7% with placebo and 13% with eplerenone (p <0.001). Table 4. 
 
Discussion 
In EMPHASIS-HF the eplerenone effect was not influenced by the eGFR i.e. the treatment effect was 
similar regardless of the eGFR stratum. However, as per stratification, eplerenone/placebo doses were 
much lower in patients with eGFR below 50ml/min/1.73m2; and despite these lower doses, side 
effects were observed more often. Therefore, using high (up to 50 mg/day) eplerenone doses in 
patients with impaired renal function may greatly increase the rate of adverse events and drug 
discontinuation. The current guidelines do not specify eplerenone dose recommendation in HFrEF and 
should thus be adapted in order to reflect the protocol of the EMPHASIS-HF trial. 
To date, no randomized trials exist directly comparing different doses of eplerenone (or any 
other aldosterone antagonist). There are, however, two large trials in which patients were 
prospectively randomized to a high or low dose of ACE inhibitor or ARB: The Assessment of 
Treatment with Lisinopril and Survival trial (ATLAS) and the Heart failure Endpoint evaluation with 
the Angiotensin II Antagonist Losartan trial (HEAAL). In ATLAS, 3,164 HF patients with an ejection 
fraction ≤30% were randomized to double-blind treatment with either low doses (2.5 to 5.0 mg daily, 
n =1596) or high doses (32.5 to 35 mg daily, n =1568) of the ACE inhibitor lisinopril. Compared with 
the low-dose group, patients in the high-dose group had a significant 12% lower relative risk of death 
or hospitalization for any reason (p =0.002) and 24% fewer hospitalizations for HF (p =0.002). Drug 
discontinuation due to side-effects was similar between groups. In HEAAL, 3,846 HF patients with an 
ejection fraction ≤40% and intolerance to ACE inhibitors were randomly assigned to low-dose (50 mg 
daily, n =1919) or high-dose (150 mg daily, n =1927) of the ARB losartan. Compared with the low-
dose group, patients in the high-dose group had a significant 10% lower relative risk of death or 
hospitalization for HF (p =0.027) and 13% fewer hospitalizations for HF (p =0.025). Drug 
discontinuation due to side-effects was also similar between groups. These findings indicate that HF 
patients should not be maintained on low doses of an ACE inhibitor or ARB (unless these are the only 
doses that can be tolerated). In contrast, MRA dose comparisons have not been perform to date. The 
design of EMPHASIS-HF was different: by stratification two dose-levels were compared with 
placebo rather than directly low vs. high treatment dose. It should be pointed out, that unlike ATLAS 
and HEAAL, EMPHASIS-HF patients were randomized within two strata which were determined by 
renal function, hence high-dose vs. low-dose treatment cannot be compared.  In EMPHASIS-HF low-
dose was as effective as high-dose eplerenone when used in appropriate patients (i.e., low-dose for 
patients with eGFR 30-49ml/min/1.73m2 and high-dose for patients with eGFR ≥50ml/min/1.73m2), 
supporting the of eplerenone at doses around 25 mg/day in patients with eGFR 30-49ml/min/1.73m2 
and around 50 mg/day in patients with eGFR ≥50ml/min/1.73m2, adapting for potassium levels when 
required. 
Stratification is usually performed to ensure that strong outcome or treatment response 
predictors are balanced between randomization groups, but stratification is also the only situation in 
which balanced randomization is maintained in subgroups, since the randomization is performed 
within each stratum12. Therefore, strata analyses are less permeable to bias caused by imbalances in 
treatment allocation and patients` characteristics, which inevitably hamper all analyses made on 
subgroups defined from non-randomized baseline characteristics. In the absence of a statistical 
interaction (i.e. similar between-strata hazard ratios, as observed herein) the treatment effect can be 
considered similar between both strata provided that the same strata-treatment doses are used in 
clinical practice. These findings, should thus change the current guidelines where no eGFR-specific 
eplerenone dose recommendation is provided1, 2; and many patients may be receiving inappropriate 
doses of eplerenone contributing to higher hyperkalemia rates and drug discontinuation13. 
In summary, the present analysis of stratified randomized data from EMPHASIS-HF provides 
robust evidence that eplerenone is equally beneficial and should be used in clinical practice at the 
respective target doses of 50 mg/day in patients with eGFR ≥50 ml/min/1.73m2 and 25 mg/day in 
patients with eGFR between 30 and 49 ml/min/1.73m2.  
 
Limitations 
This is an analysis of prespecified strata. Hence, our findings are as robust as the main randomized 
clinical trial because no statistical interaction (i.e. treatment effect differences) was observed between 
strata. 
 
Conclusion 
In EMPHASIS-HF the eplerenone effect was not influenced by the eGFR. Patients with impaired 
renal function experienced more adverse events despite receiving lower eplerenone doses. The current 
guidelines do not specify eplerenone dose recommendation according to renal function and should 
thus be adapted in the light of these data. 
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